Suomen Solubiologit ry

Yhdistys edistää solubiologian tutkimusta, koulutusta, tiedotusta ja työpaikkojen perustamista solubiologeille harjoittaen koulutus- ja tiedotustoimintaa.

Liity jäseneksi

Ajankohtaista

PhD PostDoc positions in Research Programs Unit of the Faculty of Medicine UH

22.10.2018 | Ajankohtaista
Research Programs Unit of the Faculty of Medicine is a top-quality research environment at the University of Helsinki, a leading European university with a strong life science research, and cancer research in particular. The unit is located in Biomedicum Helsinki close to the Helsinki University Central Hospital, and it provides state-of-the-art core facilities for genomics, proteomics, imaging, and bioinformatics.
PhD candidate and post-doctoral fellow (or bioinformatician/computational biologist) in the field of functional genomics (starting early 2019)

We are seeking a highly motivated and talented individual for working in the field of functional epigenomics. The focus of the lab is to investigate the interplay between transcription factors and oncogenes using modern genome-wide methods for regulatory genomic features and chromatin architecture. The group belongs to the Applied Tumor Genomics Program (starting from 2019) in the Research Programs Unit of the Faculty of Medicine in University of Helsinki providing an excellent research environment with strong focus on cancer research.

We offer a position in a young, multi-disciplinary and teamwork-oriented group that will be comprised of both computational and wet-lab scientists. The ideal candidates will be involved in generation and analysis of functional genomics datasets from next-generation sequencing methods such as ATAC-seq, Hi-C, ChIPseq, as well as CRISPR-based approaches.

– For post-doctoral fellows, the candidate should have a PhD degree in computational biology, bioinformatics or other fields with strong background in programming languages. Demonstrated skill and prior experience in the analysis of high-throughput omics datasets is required and candidates with proven track record in terms of publications will be given preference.

– For PhD students, the candidate should have a Master’s degree in any field of life sciences, other translational programs or quantitative sciences with a particular interest in molecular biology and functional genomics. A good understanding of biochemistry, genomics experiments and bioinformatics is expected. Prior experience in generating experimental omics datasets is an asset but not a requirement.

With English as a working language, excellent oral and written communication skills are required. Salaries are based on the salary system for Finnish universities (YPJ). Details on the project and other informal queries are very welcome and should be sent to biswajyoti.sahu@helsinki.fi. Applications will be considered on a rolling basis till a suitable candidate is found.

Applications should be in form of a single-pdf containing a one-page cover letter describing your research goals, interest and motivation together with recent curriculum vitae (CV) including publications. In addition, two-three reference letters with their contact details must be sent to: biswajyoti.sahu@helsinki.fi

Research Programs Unit
Faculty of Medicine
University of Helsinki
Tutkimusohjelmayksikkö, PL 63 (Haartmaninkatu 8), FI-00014 Helsingin yliopisto Forskningsprogramenheten, PB 33 (Haartmansgatan 4), FI-00014 Helsingfors universitet, Research Programs Unit, POB 63 (Haartmaninkatu 8), FI-00014 University of Helsinki, https://www.helsinki.fi/en/faculty-of-medicine/research-programs-unit

PhD student position in the Department of Biochemistry/Biotechnology, University of Turku

22.10.2018 | Ajankohtaista
Background information
A PhD student position is open in a newly started three-year project New Modalities: Recombinant Protein Platform for Drug Lead Discovery. The project aims to establish efficient strategies and tools for the development and optimization of protein based targeting molecules (antibodies and protein scaffold based binders) for drug development. The project also explores novel strategies to develop advanced antibody based drug candidates, including bispecific antibodies and antibody oligonucleotide conjugates. The project is funded by the Business Finland and is carried out in collaboration with prof. Pasi Virta (Dept. of Chemistry, UTU) and industrial partners.
 
Position
The PhD student will join the Antibody engineering research group at Unit of Biotechnology, Department of Biochemistry, University of Turku, Finland. The group has an extensive expertise in research related to recombinant antibodies and in vitro evolution techniques. The student will focus on the development of advanced biomolecular compounds including bispecific antibodies and protein conjugates. The funding from the aforementioned project is available for the period 1.11.2018 – 31.8.2021.
 
Requirements
We are seeking a highly-motivated PhD student interested in protein engineering and drug development. The applicant should hold a masters degree in biotechnology, biochemistry or biomedicine (or equivalent, or the graduation should be expected in 2018). Good spoken and written English are required. The doctoral training will contain also participation and presentations in international conferences.
 
Salary
The salary is determined in accordance with the university salary system for teaching and research personnel. For doctoral candidate the salary is at levels 2 – 4 on the job demands chart, where the task specific salary component is 2005,71 – 2500,06 euros per month. In addition, a personal work performance component will be paid. The personal work performance component is a maximum of 46.3 % of the task specific salary component. Trial period is 6 months.
 
Conditions and application deadline
The position will start at the earliest in Nov 1st 2018 .There is a trial period of six months. Send your application, CV and motivation letter at the latest Oct 18th 2018 via the electronic application form of the University of Turku. The link to the electronic application system is found at the beginning of this announcement (Apply for the job) http://www.utu.fi/en/university/come-work-with-us/open-vacancies/Pages/home.aspx
Additional information is given by Associate Professor Urpo Lamminmäki (urplammi@utu.fi)

 

Three Bachelor’s Thesis or Master’s Thesis/Internship opportunities – Novo Nordisk Foundation Center for Basic metabolic Research (CBMR), SUND, University of Copenhagen

19.10.2018 | Ajankohtaista

https://karriere.ku.dk/employer/jobs/Novo-Nordisk-Foundation-Center-for-Basic-Metabolic-Research

We are looking for three motivated and self-driven Bachelor (Thesis work) or Master students (Thesis or Internship) within the fields of biomedicine, clinical medicine, bioinformatics, pharmaceutical sciences, human biology or related fields.

Location: Novo Nordisk Foundation Center for Basic metabolic Research (CBMR), SUND, University of Copenhagen. No salary. Work language English.

Titles and starting times for the projects are:

1) Targeting Cyr61-Mediated Adipose Angiogenesis to Treat Obesity – Starting time is from the beginning of 2019 or later, Laboratory experience is an advantage.

2) Uncovering the Genetic Link between Depression and Type 2 Diabetes – Starting time as soon as the student is ready to start

3) Do healthy lifestyle factors decrease the impact of weight gain on cardio-metabolic risk in Danish individuals? – Starting time is as soon as the student is ready to start to next year.

Background for each project and related information can be found from the link along with the contact details!

Solubiologi-lehti

16.6.2018

Solubiologi 1/2018

Pääkirjoitus, 28.05.2018

Suomen kesä on alkanut erittäin lämpimästi ja kesän tuloon liittyy tietysti myös vuoden ensimmäinen Solubiologi. Tämän vuotisen kevään numeron aloittaa Marjaana Parikainen, joka avartaa meille kollageeni I:stä sitovan α2β1-integriinin roolia eturauhassyövässä, ja tämän vaikutusta geeniekspressioon ja invaasioon. Seuraavaksi Teemu Syrjälä kertoo meille brominoituneista palonestoaineista ja niiden vaikutuksista syöttösoluihin. Tämänkertaisen tietopaketin päättää Moona Huttusen ulkomaankirjeenvaihtotervehdys, jossa käydään läpi hänen jo kolme vuotta kestäneitä seikkailuitaan Lontoossa University Collegessa, Englannissa.

Tänä kesänä saimme mahdollisuuden lähteä laboratorioryhmän kanssa joukolla Suomea pakoon vierailulle TuE:hen (Technische Universiteit Eindhoven) Eindhoveniin, Hollantiin, jossa tapasimme ryhmänjohtajamme Cecilia Sahlgrenin toisen ryhmän tiimiläisiä. Ahkerana professorina Cecilia pyörittää siis kahta kokonaisuutta, ja olihan se mielenkiintoista päästä tutustumaan teknillisen yliopiston työtapoihin ja tekniikkoihin. Tämä alunperin 1956 perustettu yliopisto kouluttaa pääasiassa insinöörejä teknologian alalla, mutta solu- ja kudostekniikan ja mikrofabrikoinnin laboratoriot yhdistävät solubiologiaa ja biotekniikkaa. Yhteistyö insinöörien ja solubiologien välillä on tärkeässä asemassa TuE:ssa, kun kehitetään esimerkiksi keinotekoisia sydänläppiä tai mikrosiruja, joilla halutaan simuloida erilaisia olosuhteita, joihin solut voivat joutua. Lopullisena päämääränä on kehittää niin sanottuja organ-on-a-chip –menetelmiä, joilla voitaisiin simuloida kokonaisia elimiä pienoismallissa.

Tämä jäänee omalta osaltani päätoimittajuuteni viimeiseksi Solubiologi-lehdeksi, koska syksyllä puikkoihin tarttuu J.J. Hyvää kesän jatkoa kaikille toivottaa SEb ja koko Solubiologin väki.

– Sebastian Landor

”I am the easy-going doctor who does not need to salute properly. You will find that I am always removing my gloves. The reason for my lab coat being a slightly different color to yours is never explained.”

 

1. Artikkeli. Kollageenireseptori α2-integriini säätelee eturauhassyöpäsolujen geeniekspressiota ja invaasiota, Marjaana Parikainen (FM)

Erikoistyössä tutkittiin α2-integriinin vaikutusta eturauhassyöpäsolujen geeniekspressioon sekä solujen migraatioon ja invaasioon neljällä α2-integriiniä erilaisesti ilmentävällä DU145-solutyypillä. α2-integriinin havaittiin säätelevän tiettyjen geenien ilmentymistä sekä RNA- että proteiinitasolla mutta se ei vaikuttanut säätelemiensä proteiinien lokalisaatioon solussa. Lisäksi havaittiin, että α2β1-kollageeni I -vuorovaikutus lisäsi solutyyppien välisiä RNA-tason ilmentymiseroja suurimmalla osalla tutkituista 12 geenistä, minkä perusteella α2-integriinin aktivoituminen ja signalointi ligandivuorovaikutuksessa säätelee näiden geenien ilmentymistä. α2-integriiniä ilmentävät solut invasoivat enemmän Matrigeeliin ja kollageeni I:een kuin α2-integriiniä ilmentämättömät solut. Tulosten perusteella α2β1-integriiniin kohdentuvaa syöpähoitoa voitaisiin mahdollisesti hyödyntää eturauhassyövän luumetastaasien estämiseen.

 

2. Artikkeli. The effects of some common brominated flame retardants (bfrs) on cell degranulation and cell viability in a mast cell line, Teemu Syrjälä (Biomedical Laboratory Scientist, Bachelor of Health Care; EQF6)

The aim of this study was to investigate the effects of two commonly used brominated flame retardants, tetrabromobisphenol A (TBBPA) and hexabromocyclododecane (HBCD), on degranulation and viability of a mast cell line RBL-2H3. Assays measuring and monitoring cell viability and the release of inflammatory proteins via degranulation were developed. The results showed that both TBBPA and HBCD cause substantial cell death over a long-term exposure in vitro. Both compounds caused some degranulation of the cells, although the results from HBCD turned out to be quite modest compared to those gotten from TBBPA. TBBPA greatly induced cell death by apoptosis while only a very small degree of necrotic cell death was observed. While the degree of necrosis caused by HBCD remains unknown, it was shown to also induce apoptotic cell death at least to some extent. The study concludes that TBBPA, based on the results, does seem to be a mast cell sensitizing agent. HBCD has great potential to have similar effects, although this requires further research.

 

3. Artikkeli. Ulkomaankirjeenvaihtaja, London University College (UCL) Englanti, Moona Huttunen (FT)